Search results
Showing 6316 to 6330 of 8924 results
Simple home test prevents thousands of unnecessary bowel cancer referrals
A simple home test is sparing thousands of people from unnecessary hospital investigations for bowel cancer, while helping them get faster answers about whether they have the disease – with new data showing the impact of NICE's recommendation to use the test.
Faster, fairer access to HealthTech under new national programme
People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).
Nice has recommended the first disease modifying treatment for arginase 1 deficiency (ARG1-D), an ultra-rare, inherited and progressive metabolic disorder, for routine use in the NHS in England.
Major changes to type 2 diabetes treatment could save thousands of lives
New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.
Hidden spine fractures could be spotted earlier after NICE recommendation
NICE is recommending that quick spine checks are added to routine bone scans to help spot hidden fractures earlier and prevent serious complications.
Digital platforms recommended to help people manage their asthma
People with asthma could benefit from digital tools on their phones or tablets to help them better manage their condition, states our draft guidance published today.
New sepsis guideline targets faster, tailored treatments to benefit patients
Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]
Discontinued Reference number: GID-TA10354
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]
Discontinued Reference number: GID-TA10355
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]
Discontinued Reference number: GID-TA10356
Nintedanib for untreated malignant pleural mesothelioma [ID1424]
Discontinued Reference number: GID-TA10359
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
Discontinued Reference number: GID-TA10363
Discontinued Reference number: GID-TA10365
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
Discontinued Reference number: GID-TA10377
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380